PROVEN SUPERIOR VS AUBAGIO
Reduced Relapses
Study 1
![51 fewer](/images/51fewer.png)
Study 2
![58 fewer](/images/58fewer.png)
Fewer Active Lesions
(Gd+ T1 lesions)
Study 1
![51 fewer](/images/98fewer.png)
0.01 for KESIMPTA vs
0.46 for AUBAGIO on
average
per MRI scan
Study 2
![58 fewer](/images/94fewer.png)
0.03 for KESIMPTA vs
0.52 for AUBAGIO on
average
per MRI scan
Fewer New or Enlarging Lesions
(T2 lesions)
Study 1
![82 fewer](/images/82fewer.png)
0.72 for KESIMPTA vs
4.00 for AUBAGIO
per
year
Study 2
![85 fewer](/images/85fewer.png)
0.64 for KESIMPTA vs
4.16 for AUBAGIO
per year
Slowed Disability Progression
Studies 1 & 2 combined
![34 fewer](/images/34fewer.png)
![32 fewer](/images/32fewer.png)
*Based on whether disability progression was still present 3 and 6
months after disability symptoms started.
Gd+, gadolinium-enhancing; MRI, magnetic resonance imaging.
![Maggie image](/images/Maggie-image.png)
Since starting KESIMPTA, I've had fewer relapses,
which is really cool. I love seeing that it's really working for
me.
– MAGGIE S.
Maggie S. has taken KESIMPTA and has been compensated for her
time.
Individual results may vary.
![Maggie image](/images/Maggie-image.png)
Since starting KESIMPTA, I've had fewer relapses,
which is really cool. I love seeing that it's really working for
me.
– MAGGIE S.
Maggie S. has taken KESIMPTA and has been compensated for her
time.
Individual results may vary.
Check out KESIMPTA
experiences.
Check out the safety
profile.